16
Jan
Jan
In patients with high-risk HER2-positive breast cancer after surgery or adjuvant therapy, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared with trastuzumab alone, according to final trial results KATHERINE phase III clinical trial conducted by scientists from the University of Pittsburgh and UPMC […]